Get the Stockscreener App
26.90
0.44%
-0.12
After Hours:
27.20
0.30
+1.12%
Maplight Therapeutics Inc stock is traded at $26.90, with a volume of 181.07K.
It is down -0.44% in the last 24 hours and up +41.06% over the past month.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
See More
Previous Close:
$27.02
Open:
$26.61
24h Volume:
181.07K
Relative Volume:
0.86
Market Cap:
$1.14B
Revenue:
-
Net Income/Loss:
$-161.15M
P/E Ratio:
-7.2411
EPS:
-3.7149
Net Cash Flow:
$-138.61M
1W Performance:
+10.97%
1M Performance:
+41.06%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$26.35
$27.29
1-Week Range:
$23.77
$30.28
52-Week Range:
$12.24
$30.28
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Name
Maplight Therapeutics Inc
Sector
Industry
Phone
650-839-4360
Address
800 CHESAPEAKE DRIVE, REDWOOD CITY
Compare MPLT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
26.90 | 1.15B | 0 | -161.15M | -138.61M | -3.7149 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Needham | Buy |
| Apr-07-26 | Initiated | TD Cowen | Buy |
| Mar-19-26 | Initiated | Canaccord Genuity | Buy |
| Nov-21-25 | Initiated | Jefferies | Buy |
| Nov-21-25 | Initiated | Leerink Partners | Outperform |
| Nov-21-25 | Initiated | Morgan Stanley | Overweight |
| Nov-21-25 | Initiated | Stifel | Buy |
View All
Maplight Therapeutics Inc Stock (MPLT) Latest News
MapLight Therapeutics (MPLT): The Best Healthcare Stock Insiders Are Buying - Yahoo Finance
All News for MPLT : MapLight Therapeutics, Inc. - Zacks Investment Research
MPLT: MapLight Therapeutics, Inc.Comparison to Industry - Zacks Investment Research
MPLT : MapLight Therapeutics, Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
Maplight Therapeutics (NASDAQ:MPLT) Trading Down 6.9%Time to Sell? - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Trading 8.2% HigherStill a Buy? - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Atai Beckley N.V. (ATAI), MapLight Therapeutics, Inc. (MPLT) - The Globe and Mail
This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Sahm
9 Health Care Stocks Moving In Wednesday's Pre-Market Session - Sahm
MapLight's psychosis drug could deliver billion-dollar upside, says analyst - MSN
MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says AnalystMapLight Therapeutics (NASD - Benzinga
What date does MapLight Therapeutics, Inc.'s (MPLT) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Maplight Therapeutics (NASDAQ:MPLT) Earns Buy Rating from Analysts at Needham & Company LLC - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Hits New 52-Week HighShould You Buy? - MarketBeat
MPLT: TD Cowen Initiates Coverage with a "Buy" Rating | MPLT Sto - GuruFocus
Maplight Therapeutics (NASDAQ:MPLT) Coverage Initiated at TD Cowen - MarketBeat
Buy Rating on MapLight: Differentiated CNS Pipeline and Undervalued Schizophrenia Opportunity with Upside in Alzheimer’s and Neuropsychiatric Indications - TipRanks
MapLight2026 Funding Rounds & List of Investors - Tracxn
Maplight Therapeutics (NASDAQ:MPLT) Reaches New 52-Week HighHere's Why - MarketBeat
Stifel Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Maintains Target Price $28 - 富途牛牛
Maplight Therapeutics (NASDAQ:MPLT) Issues Quarterly Earnings Results, Misses Estimates By $1.42 EPS - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sergey Brin Nonprofit Gets $261 Million Lift in MapLight IPO - MSN
MapLight Therapeutics Announces 2025 Financial Results, Advances Clinical Pipeline for Schizophrenia, Autism, and Alzheimer’s Trials - Minichart
Maplight Therapeutics (NASDAQ:MPLT) Shares Up 5.6%What's Next? - MarketBeat
MapLight Therapeutics 2023 Annual Report: Innovative CNS Drug Discovery, Pipeline, and Risk Factors Overview - Minichart
MapLight Therapeutics Highlights Growing CNS Pipeline, Strong Cash Position - TipRanks
Stifel reiterates Buy rating on MapLight Therapeutics stock By Investing.com - Investing.com Canada
Stifel reiterates Buy rating on MapLight Therapeutics stock - Investing.com
MapLight Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MapLight Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Bitget
MapLight Therapeutics 10-K: Revenue $0, Net loss $161.2M - TradingView
[10-K] MapLight Therapeutics, Inc. Files Annual Report - Stock Titan
Earnings Flash (MPLT) MapLight Therapeutics Posts Q4 Loss $2.47 a Share - MarketScreener
MapLight Therapeutics (NASDAQ: MPLT) widens 2025 loss but funds runway through 2027 - Stock Titan
Two Phase 2 readouts ahead as MapLight says cash lasts through 2027 - Stock Titan
Top Maplight Therapeutics (MPLT) Competitors 2026 - MarketBeat
MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to S&P Global BMI Index - MarketScreener
Maplight Therapeutics (NASDAQ:MPLT) Cut to Sell at Wall Street Zen - MarketBeat
MapLight Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | MPLT | US56565P1030 - marketscreener.com
Canaccord Genuity Group Begins Coverage on Maplight Therapeutics (NASDAQ:MPLT) - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Shares Down 3.1%Should You Sell? - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 8.9%Here's What Happened - MarketBeat
MapLight Therapeutics to join Russell 3000, Russell 2000 and Russell Microcap indexes - MSN
MapLight Therapeutics: Sector Dynamics Take Center Stage Amid Company Quiet () - aktiencheck.de
MapLight Therapeutics Director Makes Bold Insider Move in Latest Stock Buy - TipRanks
Schizophrenia Clinical Trial Pipeline Expands as 55+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | Sunovion Pharmaceuticals, AbbVie, Karuna Therapeutics - Barchart.com
Autistic Disorder Pipeline Expands with 25+ Companies and 25+ Therapies in Development Across Clinical Stages, Reveals DelveInsight - Barchart
Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity - finviz.com
MPLT Earnings History & Surprises | EPS & Revenue Results | MAPLIGHT THERAPEUTICS INC (NASDAQ:MPLT) - ChartMill
Maplight Therapeutics Inc Stock (MPLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Maplight Therapeutics Inc Stock (MPLT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Malenka Robert C. | Director |
Feb 20 '26 |
Sale |
18.03 |
2,195 |
39,576 |
337,059 |
| Malenka Robert C. | Director |
Feb 24 '26 |
Sale |
18.15 |
736 |
13,358 |
325,059 |
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):